Latest Nitric oxide Stories
COCOA, Fla., June 9, 2011 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced it has been awarded a new patent for its NITROSYL(TM) (Inhaled Nitric Oxide) Systems. U.S. Patent No.
Patients with pulmonary arterial hypertension struggle with severe symptoms, which include shortness of breath, exhaustion and a lack of vitality.
Exercise both reduces the risk of a heart attack and protects the heart from injury if a heart attack does occur.
Yuemeng Dai, MD, PhD, of Little Rock, AK, will receive the first place Bill Postic Basic Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Enos Protein Expressions is Decreased in Involuting Hemangiomas,"during their annual meeting, April 29 â€“ May 1, 2011, in Chicago, IL.
CLINTON, N.J., April 11, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced the introduction of its next-generation drug-delivery system, the INOMAX DSIR, in neonatal intensive care units (NICUs) within hospitals throughout the United States.
COCOA, Fla., April 5, 2011 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced that it received a sixth patent on its inhaled NITROSYL(TM) nitric oxide (NO) product.
Disorders of the circulatory system- vascular diseases- are common in the developed world, and can lead to heart attacks, strokes and even death.
COCOA, Fla., March 22, 2011 /PRNewswire/ -- GeNO LLC (www.genollc.com), a privately held, advanced development-stage technology company, today announced commencement of the PHiano Study: A Phase 2, Dose-Escalation Trial for the Treatment of Pulmonary Hypertension in patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF) using Inhaled NITROSYL(TM) nitric oxide (NO).
Inhaling nitric oxide gas does not reduce pain crises or shorten hospital stays in people living with sickle cell disease.
Among patients with sickle cell disease, treatment of a vaso-occlusive crisis (characterized by episodes of severe pain) in the hospital with inhalation of nitric oxide gas for up to 3 days did not result in a shorter time to resolution of the pain, compared to patients who received placebo.
- An imitative word; an onomatopoetic word.